http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114948359-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa47ed256e1fb66b346ad46a238d24cc
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2310-0097
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2250-0067
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2240-002
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B33Y10-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B33Y30-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-0077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-82
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B33Y30-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B33Y10-00
filingDate 2022-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa11b604e0a8026443bcd63ca75c6663
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23191fabfbdbca269a0210f66ddbc07c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1637fb1c02edbada452d9772bba0f02
publicationDate 2022-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-114948359-A
titleOfInvention A kind of targeted drug delivery stent and its 3D printing preparation method and application
abstract The invention discloses a targeted drug delivery stent and a 3D printing preparation method and application thereof, and relates to the technical field of stents. The 3D printing preparation method of the targeted drug delivery stent includes: establishing a patient stent model through the development contour of the patient image data; marking the patient stent model through the tissue thickness difference value in the patient image data to distinguish the lesion area from the normal area; It is integrally formed or assembled and coated to prepare a drug-targeted stent. The normal area does not have the drug-loaded material, and the diseased area has the drug-loaded material. The shape and structure of the prepared stent for targeted drug delivery better match the narrow channel that the patient needs to expand, which is beneficial to subsequent implantation. At the same time, the division of the normal area and the diseased area can ensure that the drug is targeted to treat the diseased area, and further Effectively avoid the negative impact of the drug on the non-lesioned normal area, and finally achieve the therapeutic effect of the stent inhibiting the lesion to the greatest extent and affecting the normal tissue to the least extent.
priorityDate 2022-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID373926
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559477
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP22775
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP81070
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID107689
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID409982724
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23963
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID395837
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO01945

Total number of triples: 31.